Non-vertebral fracture benefit from oral ibandronate administered daily or with a unique drug-free interval: Results from a pivotal phase III study in postmenopausal osteoporosis (PMO).

被引：0
|
作者：
Recker, R
Stakkestad, JA
Weber, T
Cohen, S
Delmas, P
Schimmer, R
Mahoney, P
Kilbride, J
机构：
[1] F Hoffmann La Roche & Co Ltd, CH-4002 Basel, Switzerland
[2] Hop Edouard Herriot, Lyon, France
[3] Metroplex Clin Res Ctr, Dallas, TX USA
[4] Duke Univ, Med Ctr, Durham, NC USA
[5] CECOR AS, Haugesund, Norway
[6] Creighton Univ, Sch Med, Omaha, NE USA
来源：
JOURNAL OF BONE AND MINERAL RESEARCH | 2002年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1038
引用
下载
收藏
页码：S134 / S134
页数：1
相关论文
共 17 条
  • [1] Oral ibandronate significantly reduces fracture risk in postmenopausal osteoporosis when administered daily or with a unique drug-free interval: Results from a pivotal phase III study
    Delmas, P
    Recker, R
    Stakkestad, JA
    Chestnut, C
    Hoiseth, A
    Weichselberger, A
    Huss, H
    von Stein, T
    Schimmer, R
    OSTEOPOROSIS INTERNATIONAL, 2002, 13 : S15 - S15
  • [2] Benefits of oral ibandronate on non-vertebral fracture risk in postmenopausal osteoporosis: Further analyses from a pivotal phase III study
    Emkey, R.
    Chesnut, C. H.
    Schimmer, R. C.
    Neate, C.
    Recker, R. R.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2007, 22 : S329 - S329
  • [3] Oral ibandronate reduces non-vertebral fracture risk in postmenopausal osteoporosis: Results from a sub-analysis of a pivotal study
    Stakkestad, Jacob A.
    Emkey, Ronald
    Neate, Colin
    Chesnut, Charles H.
    BONE, 2008, 42 : S86 - S86
  • [4] Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies
    Harris, Steven T.
    Blumentals, William A.
    Miller, Paul D.
    CURRENT MEDICAL RESEARCH AND OPINION, 2008, 24 (01) : 237 - 245
  • [5] Oral daily and intermittent ibandronate significantly reduce the incidence of new vertebral fractures: Results from a multinational phase III fracture study
    Felsenberg, D
    Lorenc, R
    Hughes, C
    Schimmer, RC
    Wasnich, R
    OSTEOPOROSIS INTERNATIONAL, 2003, 14 : S71 - S72
  • [6] Upper gastrointestinal safety profile of oral daily and intermittent ibandronate: Results from a large pivotal phase III study
    Delmas, PD
    Skag, A
    Chesnut, CH
    Stakkestad, JA
    Christiansen, C
    Hoiseth, A
    Benevolenskaya, L
    Recker, R
    Leishman, B
    Mahoney, P
    Schimmer, R
    OSTEOPOROSIS INTERNATIONAL, 2002, 13 : S15 - S15
  • [7] Histomorphometric evaluation of daily and intermittent oral ibandronate in women with postmenopausal osteoporosis: Results from the BONE study
    Recker R.R.
    Weinstein R.S.
    Chesnut III C.H.
    Schimmer R.C.
    Mahoney P.
    Hughes C.
    Bonvoisin B.
    Meunier P.J.
    Osteoporosis International, 2004, 15 (3) : 231 - 237
  • [8] Oral daily and intermittent ibandronate normalize bone turnover and significantly reduce vertebral fracture risk: Results from a large phase III study.
    Emkey, R
    Recker, RR
    Stakkestad, JA
    Mahoney, P
    Schimmer, RC
    JOURNAL OF BONE AND MINERAL RESEARCH, 2003, 18 : S372 - S372
  • [9] Significant reduction in vertebral fracture risk: Evidence for the efficacy of daily and intermittent ibandronate from a large phase III study
    Christiansen, C
    Chesnut, CH
    Delmas, PD
    Skag, A
    Recker, RR
    Stakkestad, JA
    Hoiseth, A
    Felsenberg, D
    Gilbride, J
    Schimmer, RC
    ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 : 94 - 95
  • [10] Oral daily and intermittent ibandronate provide significant and sustained reductions in height loss in postmenopausal osteoporosis: Results from the bone study
    Delmas, PD
    Hoiseth, A
    Gilbride, J
    Schimmer, RC
    Chesnut, CH
    OSTEOPOROSIS INTERNATIONAL, 2003, 14 : S75 - S75
12